Taysha Gene Therapies, Inc. (TSHA) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Taysha Gene Therapies, Inc. (TSHA) Earnings Overview
As of June 23, 2026, Taysha Gene Therapies, Inc. (TSHA) reported trailing twelve-month net income of -$130M, reflecting +5.6% year-over-year growth. The company earned $-0.35 per diluted share over the past four quarters, with a net profit margin of -1115.3%.
Looking at the long-term picture, TSHA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2019.
Taysha Gene Therapies, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), TSHA has room to improve margins relative to the peer group. Compare TSHA vs SRPT →
TSHA Earnings vs Peers
Earnings metrics vs comparable public companies
TSHA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$109M | -22.1% | -$110M | $-0.34 | -1115.3% | -1130.6% |
| 2024 | -$89M | +20.0% | -$91M | $-0.36 | -1071.6% | -1097.6% |
| 2023 | -$112M | +32.8% | -$72M | $-0.96 | -722.1% | -468.8% |
| 2022 | -$166M | +4.9% | -$126M | $-3.78 | -6635.3% | -5037.1% |
| 2021 | -$175M | -305.9% | -$173M | $-4.64 | - | - |
| 2020 | -$43M | -3756.5% | -$43M | $-3.40 | - | - |
| 2019 | -$1M | - | -$1M | $-0.03 | - | - |
Download Data
Export TSHA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TSHA — Frequently Asked Questions
Quick answers to the most common questions about buying TSHA stock.
What is TSHA earnings per share (EPS)?
TSHA trailing twelve-month (TTM) diluted EPS is $-0.35, reflecting +5.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Taysha Gene Therapies, Inc.'s net income?
Taysha Gene Therapies, Inc. (TSHA) trailing twelve-month net income is $-130M as of 2025. Earnings grew +5.6% year-over-year.
Is TSHA profitable?
TSHA is not currently profitable on a TTM basis, reporting a net loss of $-130M. Net margin is -1115.3%. Investors should monitor for a return to profitability.
What is TSHA's earnings growth rate?
TSHA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are TSHA's profit margins?
Taysha Gene Therapies, Inc. net profit margin is -1115.3%, operating margin is -1130.6%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -68.5%.
Is TSHA growing earnings?
TSHA is growing earnings steadily. YoY EPS growth of +5.6% is consistent with the 5-year CAGR of N/A. TTM net income is $-130M.
What was TSHA's best earnings year?
Taysha Gene Therapies, Inc.'s highest annual net income on record is $-1M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were TSHA's earnings last quarter?
TSHA's most recent reported quarter was Q1 2026. Net income was $-42M with diluted EPS of $-0.12. For a full breakdown of all quarters, see the quarterly earnings table on this page.